Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the US, China and Japan January 18, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
Bio-Sourcing, Zerion Pharma to Collaborate on First HER2 Oral Monoclonal Antibody for Breast Cancer January 18, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer January 18, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop RC148 for Advanced Solid Tumors January 18, 2026
Ferring Pharmaceuticals and Theralase Technologies to Investigate ADSTILADRIN – Ruvidar (TLD-1433) Combo in Bladder Cancer January 18, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
TROPION-Lung17 TROP2 Biomarker Directed Ph 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous NSCLC January 18, 2026
Ph 3 KANDLELIT-007 Trial of Calderasib + KEYTRUDA QLEX™ Merck Initiated in Certain Patients With Advanced NSCLC January 18, 2026
Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Ph 3 EPCORE® DLBCL-1 Trial in Patients with R/R DLBCL Announced January 18, 2026
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma from the eNRGy Trial January 18, 2026
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat CRC January 18, 2026
Positive Follow-Up Data from Ph 2 Trial Shows Extended Long-Term OS Benefit with Elraglusib + Chemo for Metastatic Pancreatic Cancer January 18, 2026
Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in NSCLC Announced January 18, 2026
Ph 1/2a Data of IMC002 Highlighted a Durable Complete Response Beyond 1 Year and a 66.7% ORR in Advanced GC/GEJ January 18, 2026
Results from SACHI Ph 3 trial of savolitinib and osimertinib combination in EGFR mutation+ve NSCLC patients with MET amplification published in The Lancet January 18, 2026
TECVAYLI monotherapy demonstrates superior PFS and OS vs SOC in patients with R/R multiple myeloma January 18, 2026
Vigil Demonstrates Significant Survival Benefit in cTMB-H/HRP Ovarian Cancer Patients; Ph 2b VITAL Trial Analysis Published in JCO – Precision Oncology January 18, 2026
Positive Biomarker Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced January 18, 2026
Durable Complete Response of 15 Months with a Chemo-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma Announced January 18, 2026
FDA grants Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer January 18, 2026
